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STRUCTURE, FUNCTION, AND USE OF 
CORTICOSTEROIDS 
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ABSTRACT 
Dexamethasone, a powerful corticosteroid, is a frequently used drug in the realm of veterinary 
medicine. However, many times it is used without prior knowledge as to why or how it may produce 
the desired effect, or without consideration as to the best method of administration. 
The purpose of this project is two-fold. First, it will consist of some basic research in order to 
clarify the mode of action of dexamethasone. In brief, corticosteroids are hormones produced by the 
adrenal gland, which is located adjacent to the kidney. The production of corticosteroids is subject 
to feedback regulation, where a build-up of corticosteroid will shut down the production of any 
further hormone. 
The second phase of this project consists of a field study using six equines. Dexamethasone, a 
synthetic corticosteroid, was administered both IV (intravenously) and IM (intramuscularly) to 
determine the effects on regulation of the production of corticosteroids. The initial hypothesis was 
that blood cortisol levels would be equally suppressed in horses given dexamethasone IV as in those 
given dexamethasone IM. The final results of the study served to support this hypothesis. 
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CORTICOSTEROIDS: A LOOK AT BASIC STRUCTURE AND 
FUNCTION 
INTRODUCTION 
The human body is undeniably complicated. Yet in its complexity, it is incredibly 
efficient and accurate in its functional abilities. One example of this is its ability to 
synthesize and respond to a group of hormones known as glucocorticoids (or 
glucocorticosteroids), produced by the adrenal cortex. In this paper, the glucocorticoids will 
be introduced, covering areas of basic structure, pathway of synthesis, secretion and binding 
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All of the steroid honnones (including glucocorticoids) have the some basic core structure, 
consisting of three six-carbon rings and one five-carbon ring. In order for them to have their 
anti-inflammatory and glucogenic ability, they must have a functional hydroxyl group (-OH) 
at carbon 11. Additionally, they nlust have a functional-OH group at carbons 21 and 17 in 
order to be maximally active. In this form, with an -OH at carbons 21 and 17, the steroid is 
"said to be in its alcohol fonn. As such, it is classified as a lipid with the characteristic result 
that it is insoluble in water. 
Because of its insolubility, a steroid will require a protein carrier in order to travel in an 
aqueous media (i.e. the plasma). The steroid will then be released into its target cells from 
the protein-honnone complex fairly slowly, in contrast to some synthetic steroids which are 
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water soluble, do not require a carrier, and are released quickly to their targets. 
Additionally, there are different ways in which steroids can be chemically modified. Using 
hydrocortisone as an example, there is esterification at carbon 21. The addition of succinate 
or phosphate at this location will result in a compound that is truly water soluble. However, 
esterification at carbon 21 with butylacetate, acetate, acetonide, methyl acetate, dipropionate, 
or pivalate causes the formation of a water insoluble ester form of the lipid that traverses 
membranes much more slowly than the succinate and phosphate forms. However, since this 
causes the hydrocortisone to be absorbed more slowly, it also tends to increase the duration 
of its action. 
However, in order to be active, these esters must be hydrolyzed after crossing the 
membrane in order to convert the carbon at position 21 back to its active -OH form. This 
conversion, which takes place intracellularly, occurs most rapidly for phosphate and 
succinate esters, while other forms take longer. 
There are also several alterations which can be made to the basic structure of 
hydrocortisone that produce changes in its activity. Fonning a double bond between carbons 
1 and 2, adding fluorine, adding a methyl group, and adding an -OR group all can lead to 
increased anti-inflammatory potency and increased gluconeogenic potency_ 
BIOSYNTHESIS 
The biosynthesis of glucocorticoids begins with the breakdown of cholesterol. The 
pathway for the formation of cortisol, the most common glucocorticoid in humans, is known 
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to be cholesterol ---> pregnenolone ---> progesterone ---> 17 -hydroxyprogesterone ---> 
cortisol. The convert ion of cholesterol to 5-pregnenolone is carried out by a series of 
enzymes found in the mitochondria of the adrenal cortex. The fITst reaction results in the 
formation of a 2Oct..-hydroxyl in the side chain of the cholesterol molecule by a 2(){-
hydroxylase enzyme, followed by hydroxylation at the 22 position by 22-hydroxylase 
enzyme, yielding 20x -22 )-dihydroxycholesterol. Both of the hydrolase enzymes require 
NADPH for the introduction of molecular oxygen to form the hydroxyl group. Then, a 
cleavage occurs between the hydroxyl groups at the 20 and 22 positions by a desmolase 
enzyme. This yields two products, 5-pregnenolone and isocaproid aldehyde. An interesting 
fact which will bear more importance later on in this paper is that the reaction sequence of 
cholesterol ---> 5-pregnenolone in the mitochondria has been considered to be one of the 
principal sites at which ACTH is able to regulate steroidogenesis. 
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The enzymes mvolveoln th~ patlfway of cholesterol ---> 5-pregnenolone can be stimulated 
by the metabolism of citric acid cycle substrates such as isocitrate, malate, and succinate, 
which generate reducing equivalents for the respiratory chain leading to steroid 
hydroxylation. They can also be stimulated by an increased rate of reduction ofNADP+ 
generated from the glucose-6-phosphate dehydrogenase reaction found in the pentose 
phosphate pathway. Additionally, high levels of ACTH in the blood can also stimulate the 
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conversion of cholesterol to pregnenolone. 
The next step in the sequence of steroidogenesis sees the chemical conversion of 
pregnenolone into progesterone, a series of reactions which also occur in the mitochondria 
of the adrenal cortex. The fITst reaction is the removal of two hydrogens from the -CHOH 
group at position 3 by a 3-hydroxysteroid dehydrogenase specific for pregnenolone, which 
uses NAD+ as an electron acceptor. Thus, the enzyme converts the 3-hydroxyl group to a 
3-ketone. The NADH formed may be reoxidized in the mitochondrial electron-transport 
sequence. The second enzyme in this sequence is called 45 -3-ketosteroid isomerase and 
results in the shift of the double bond from the 5 to the 4 position, yielding the product 
progesterone. 
The final two steps in the formation of cortisol are less complex. Progesterone is 
converted to 1 ']PC -Hydroxyprogesterone by the enzyme 170( -Hydroxylase, which utilizes 
NADPH as an electron donor. The enzymes 21 and 11 hydroxylases then convert 170< -
hydroxyprogesterone into 171{ - hydroxycorticosterone (hydrocortisone). This completes the 
pathway of the convertion from cholesterol ---> hydrocortisone. 
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As the synthesis of hydrocortisone occurs in the mitochondria of the adrenal cortex, it is 
useful to examine the system by which this synthesis is controlled. The hypothalamus, the 
anterior portion of the pituitary gland, and higher centers in the brain all work together to 
regulate the activity of the adrenal cortex and thus the levels of glucocorticosteroids in the 
blood. In this physiological pathway, the higher centers of the brain may send nervous 
signals to the hypothalamus. The hypothalamus responds by releasing Corticotropin 
Releasing Factor (CRF) into the blood supply, allowing it to be carried to the anterior 
pituitary. The CRF then stimulates the anterior pituitary to release Adrenocorticotropic 
Honnone (ACTH). ACTH travels in the blood stream to the adrenal cortex where it causes 
the release of hydrocortisone into the animals blood stream, thus being distributed to all 
eyc:lt>,',,: 
H-i5hw ce.;"\.t-Q. ... s tissues of the body. 
The fITst one 
involves steroid feedback, where the level of hydrocortisone in the plasma regulates further 
hydrocortisone release from the adrenal cortex by a feedback mechanism. This feedback 
mechanism occurs at the level of the hypothalamus. Additionally, it is interesting to note 
that the hypothalamus cannot tell the difference between hydrocortisone and some of the 
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chemically synthesized analogues such as Prednisolone, Dexamethasone, or Flumethasone. 
Thus, injection with any of these drugs will lead the hypothalamus to conclude that levels 
of hydrocortisone are high, thus decreasing production of CRF. An interesting study 
published by Altemus et al. in 1997 examined the reduced sensitivity to glucocorticoid 
feedback and reduced glucocorticoid receptor mRNA expression in the luteal phase of the 
menstrual cycle. The results indicated that reduced glucocorticoid feedback regulation of 
the hypothalamus-pituitary-adrenal axis may playa role in the generation of the common 
premenstrual symptoms of irritability and dysphoria. 
The second control mechanism used involves the nervous system. As the nervous system 
is sensitive to changes in environment, it may respond by sending stimuli to the higher 
centers of the brain, beginning the pathway that leads to the production of hydrocortisone. 
By this means, animals are able to adapt to stress. Hannful stress stimuli such as fear, noise, 
allergic reactions, and trauma tum this system on and increase the release of hydrocortisone. 
GL YCOL YSIS AND GLUCONEOGENESIS 
One of the important functions of glucocorticosteroids in the body is their role in the 
production of glucose from short-chain precursors by gluconeogenesis. In this process, 
glucocorticosteroids act to inhibit protein synthesis in peripheral tissues, thus releasing free 
amino acids from muscle and other tissues to the liver. Once in the liver, these amino acids 
then undergo transamination and other reactions to fonn pyruvate or oxalacetate, and then 
eventually are converted into glucose by the gluconeogenic pathway. The nitrogen from the 
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amino acids is converted to urea by the liver. Furthennore, glucocorticosteroids also 
increase the breakdown of lipids in adipose tissues, thus releasing free fatty acids and 
glycerol. Glycerol is a precursor of glucose in the liver, whereas free fatty acids inhibit the 
utilization of glucose by the liver. Thus, the initial effects of glucocorticosteroids is to 
increase amino acid precursors for synthesis of glucose and, due to an increase in free fatty 
acid from adipose tissue, to decrease the activity of enzymes involved in the breakdown of 
glucose. 
There are some additional early effects of glucocorticosteroids, although these seem to be 
secondary. Firstly, they induce the synthesis of transaminases which are involved in the 
fonnation of keto acid precursors from amino acids. Additionally, they seem to stimulate 
the synthesis of gluconeogenic enzymes concerned in the synthesis of glucose from the keto 
acids. 
However, it should be noted that the action of the glucocorticosteroids can also have some 
disastrous effects if used in excess. A study perfonned in 1997 by McKay et al. 
demonstrated that some common side effects of corticosteroid therapy include muscle 
weakness and atrophy, which in part are mediated by the induction of glutamine synthetase. 
Additionally, reabsorption of bone matrix along with calcium, possible increased blood 
sugar, and increased glycogen deposition in the liver are also seen to occur. Furthennore, 
some of the glucose which is produced in excess of the body's needs may be converted into 
fat. 
When the levels of sugar in the blood become low, two honnones are released. Glucagon, 
-7-
the first honnone indirectly activates the enzyme phosphorylase a in the liver, leading to the 
breakdown of glycogen to fonn glucose. It also activates liver lipases for an increased 
breakdown of liver lipid with a release of free fatty acids and glycerol, the effects of which 
have already been examined. Epinephrine, the other honnone released in response to low 
blood sugar, leads to an increase in phosphorylase a. Like glucagon, it also stimulates lipase 
in the adipose tissues, thereby releasing free fatty acid and glycerol. But is also has an effect 
in stimulating the release of lactate from muscle, thus providing some precursors for 
gluconeogenesis. In addition, the most pertinent point is that epinephrine also is apparently 
a mediator in stimulating the release of ACTH from the anterior pituitary in response to a 
decrease in blood glucose. This increase in ACTH stimulates the adrenal cortex for an 
increased production of corticosteroids. 
GLUCOCORTICOSTEROIDS AND THE IMMUNE RESPONSE 
In addition to the effects of the steroid honnones on gluconeogenesis and glycolysis, the 
glucocorticosteroids are also important in tlleir antiallergic and antiinflammatory actions. 
They are able to cause an initial lysis of the lymph nodes with increased release of 
antibodies. However, there is ultimately a decreased production of antibodies. The overall 
effect is the suppression of the function of the lymphoid tissues, the tissues responsible for 
the production of antibodies. Additionally, the glucocorticosteroids decrease the cellular 
response to infection by decreasing the phagocytic ability of neutrophils and lymphocytes, 
thereby reducing the inflammation without clearing up the infection. However, the actual 
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neutrophil count usually increases, although their activity is decreased. Additionally, 
glucocorticosteroids are able to decrease the formation of histamine and histamine-like 
substances in cells, thereby reducing the allergic response. Since they also cause a decrease 
in the eosinophil count, they can lead to a decrease in inflammation. Eosinophils are 
abundant at sites of immediate hypersensitivity reactions, and in this setting they contribute 
to tissue injury and inflammation. By lowering their count, glucocorticosteroids held 
decrease visible inflammation. 
Furthermore, glucocorticosteroids have been shown to increase the stability of cell 
membranes and lysosomal membranes, thus decreasing the release of inflammation 
enhancing toxic products from injured cells and from lysosomes, as well as decreasing the 
cellular insult of toxins. By stabilizing these membranes, the activation of lipases and 
phospholipases is prevented, thus preventing the supply of free arachidonic acid that triggers 
the formation of eicosanoids. Finally, glucocorticosteroids inhibit prostaglandin production 
by macrophages. Prostaglandins, which are part of the 20 carbon containing atoms known 
as "eicosanoids", are known to stimulate inflammation, and thus their inhibition would 
partially account for the decrease in inflammation observed upon injection of an individual 
with glucocorticosteroids. 
Finally, it is also known that glucocorticoid hormones are able to inhibit T -cell growth and 
activation. A recent study performed by Migliorati et al. has suggested that the down-
modulation of the T -cell receptor expression is due to the diminution of T -cell receptor gene 
products in cells treated with exogenous glucocorticoids. 
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GLUCOCORTICOID RECEPTORS 
At the cellular level, the many effects of glucocorticosteroids are medicated by the glucocorticoid 
receptor. These receptors appear to be located in the cytoplasmic compartment of the cell, and thus 
the first step in glucocorticoid action is for the hormone to gain entry into the cell. Generally, steroid 
hormone uptake is generally considered to occur by simple diffusion, but it is possibly that specific 
carriers are involved in steroid hormone uptake. Following this entry into the cytoplasm, the 
hormone must bind to its appropriate receptor. The glucocorticoid receptor is a relatively 
nonabundant protein in cells, and is distinguishable by two basic characteristics. Firstly, it binds 
hormones with high affinity. This high affinity is necessary because of the low concentrations at 
which glucocorticoid hormones are generally present within the cell. Secondly, the glucocorticoid 
receptor binds hormones with a high degree of specificity, and thus has very low affinity for other 
classes of steroid hormones (i.e. androgens, estrogens). Additionally, the association between the 
glucocorticoid receptor and its ligand is noncovalent. An interesting fact is that several transition 
metals and their anions, including cadmium, arsenite, and selenite can inhibit glucocorticoid binding 
to receptors. A study published by Telford and Fraker in 1997 shoed that zinc has an inhibitory effect 
as well. After this receptor/ligand binding takes place, the receptor undergoes activation to a DNA-
binding form. In the absence of hormone, the receptor is unable to bind DNA, but the binding of the 
hormone converts it into its active form. Subsequently, the glucocorticoid receptor translocates into 
the nucleus of the cell. Because of its rather large size (approximately 97 kd), it is most likely that 
the receptor/ligand complex enters the nucleus via a facilitated transport mechanism rather than by 
simple diffusion. Finally, the glucocorticoid receptor will associate with specific sequences in the 
genome which are known as glucocorticoid response elements. These response elements regulate 
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the rate of transcription initiation from nearby promoters, causing an increase in the transcription of 
specific genes. For example, a study performed by Nuglozeh et al. In 1997 showed that 
glucocorticoids have transcriptional and posttranscriptional effects on rat mesenteric artery cells 
through glucocorticoid receptors. The glucocorticoid response element has a consensus sequence 
ofTGTTCT, and has been detected as close as 39 base pair and as far as 2.6 kilobase pair upstream 
of the transcription start site, and between 100 base pair and 8 kilobase pair downstream from the 
initiation site. Additionally, there is also evidence that the glucocorticoid receptor is also able to act 
posttranscriptionally to influence the levels of rrtRNA present, either by altering RNA stability or by 
stimulating the transport of specific RNA species from the nucleus to the cytoplasm. 
It is now known that the different regions of the glucocorticoid receptor have different functions, 
and thus are considered separate domains. These discoveries were made when the receptor was 
incubated with trypsin, resulting in three receptor fragments. The first two fragments arise from the 
carboxy terminal half of the receptor, where they bind DNA and hormone, respectively. The third 
fragment stems from the amino terminal of the receptor, and it reacts with most anti-receptor 
antibodies, which are often used in the purification of the protein. Because this third domain is able 
to bind to antibodies, it is thought that it constitutes the exposed surface when the receptor is in its 
native conformation. 
As was already mentioned, it appears that the receptor is inactive and unable to bind DNA when 
in its unbound state. The process whereby hormone binds to its receptor and mediates a change to 
the DNA-binding state is known as "receptor activation". Basically, there are two generally models 
of receptor activation. In the first, known as the oligomer dissociation model, the oligomeric 
structure renders the DNA-binding site inaccessible for interaction with DNA. On binding hormone, 
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the oligomer dissociates, and thus exposes the DNA-binding site on the receptor. The second model 
of activation is referred to as the conformational model. In this model, the function of the DNA 
binding region is repressed by the steroid-binding domain. When the hormone binds, the 
conformation of the receptor changes, rendering the DNA-binding site accessible to DNA. Generally 
speaking, these two models are extremely simplified, because there are additional factors involved 
in activation. One example has been termed "modulator". Modulator is a phosphoglyceride that 
functions as an endogenous inhibitor of glucocorticoid receptor activation. 
The intracellular concentration of glucocorticoid receptors is largely responsible for the magnitude 
of the cellular response to glucocorticoids. Studies have indicated that the intracellular 
concentration of glucocorticoid receptors is under autoregulatory control. Thus, many 
glucocorticoids are able to downregulate the level of their own receptor. This downregulation is 
relatively slow, taking at least 24 hours of steroid exposure to cause a notable decrease in receptor 
content. Furthermore, on removal of the agonist, the glucocorticoid receptor downregulation is 
reversed. During the period of receptor repletion, no altered forms of the glucocorticoid receptor 
have been identified. There are several possible mechanisms responsible for the autoregulation. In 
the first, the intracellular concentration of receptors may be determined by modulation of receptor 
half-life. Some studies have shown that the half-life of the glucocorticoid receptor appears to be 
shorter in the presence of hormone than in the absence of hormone. Secondly, the intracellular 
receptor concentration can be regulated at the transcriptional level. Thus, the level of receptor 
mRN A is decreased in response to glucocorticoids. It appears that the glucocorticoid receptor 
downregulation may be caused by an interaction of the receptor protein with its own gene. Thirdly, 
the receptor may be degraded by proteolysis, as there several calcium dependent enzymes that can 
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degrade receptors are known to exist at specific loci. Finally, it is possible that the receptor my exist 
in two forms, on an active hormone-binding state and one an inactive nonhormone-binding state. It 
is possible that the conversion to the steroid-binding form requires the hydrolysis of ATP. This was 
confirmed in an experiment which showed that the receptor binding capacity of the IM -9 line of 
human lymphyoblasts was directly related to the ATP levels when cells were incubated under energy 
limiting conditions. This conversion from the nonhormone binding to the hormone binding form was 
both reversible and rapid. The exact function of the ATP is unknown. It is possible that the receptor 
maybe phosphoylated by ATP in an enzyme dependent reaction. Recently, Miller et al. presented 
the hypothesis that the receptor is itself a kinase, and is capable of autophosphorylation in the 
presence of ATP. However, it remains uncertain whether phosphorylation actually controls binding 
capacity or whether the ability to bind steroids may depend more on the receptors ability to form a 
complex with ATP. 
Additionally, a recent study published by Numi et al. examined the participation of tyrosine kinase 
in the regulation of the glucocorticoid receptor by using the tyrosine kinase inhibitor herbmycin A. 
Their findings showed that tyrosine kinase is necessary for maintaining the level of glucocorticoid 
receptor protein and its affinity of binding sites in the cytosolic fraction. 
CONCLUSION 
Consequently, it can be seen that glucocorticosteroids are able to playa large roll in 
the functioning of the human body, as well as in other animals. They are currently being 
used as therapy to treat such conditions as skin inflammations and hypoglycemia. As 
more becomes known about them and their beneficial and also possibly harmful effects, it 
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is likely that the medical and scientific worlds will receive great benefits. For example, 
work is currently being done to determine if prenatal stress might possibly impair the 
coping and regulation of the hypothalamic-pituitary-adrenal (HPA) axis. Typical 
characteristics of prenatally stressed infants include attentional deficits, hyperanxiety, and 
disturbed social behavior. These symptoms are often associated with dysregulation of the 
HP A axis, characterized by decreased feedback inhibition of corticotropin-releasing 
hormone and prolonged elevation of plasma glucocorticoids in response to stress. It has 
been proposed that the impaired ability to deal with stressful situations by the prenatally 
stressed infants may be a result of the action of maternal hormones released during 
periods of stress. It is now believed that if enacted during a critical time in fetal 
development, gestational stress may increase the probability of developing this disorder. 
It is this type of research that will hopefully lead to a more useful knowledge of 
glucocorticoids in the near future. 
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1. Introduction 
Corticosteroids are a naturally occurring hormone found in the equine body. They are released by 
the adrenal cortex following a multi-step pathway in which the adrenal cortex is stimulated to produce 
corticosteroids by the presence of Adrenocorticotropic Hormone (ACTH) in the bloodstream. When 
levels of corticosteroids are elevated in the blood, endogenous production is decreased as a result of 
feedback inhibition which directly affects levels of ACTH in the blood. 
Because of the complexities involved in the feedback mechanism, administration of exogenous 
ACTH or corticosteroids (i.e. dexamethasone) can upset the general balance. If corticosteroids are 
given over an extended period of time, production of ACTH by the pituitary will decrease, thus 
signaling the adrenal cortex to down-regulate its production of corticosteroids. This decrease in 
stimulation by ACTH will cause the adrenal cortex to atrophy, and corticosteroid production will 
either decrease or stop. If exogenous treatment is suddenly withheld, there is often a severe 
endocrine imbalance due to an inability to produce endogenous corticosteroids. 
In this study, dexamethasone will be administered to horses in two ways, either 1M or IV. One of 
the most prominently excreted forms of corticosteroids in the body is cortisol (hydrocortisone). 
However, the body cannot distinguish between cortisol and the different man-made analogues such 
as dexamethasone. Thus, dexamethasone will be recognized as a natural corticosteroid, leading to 
repression of the endogenous production of cortisol. By measuring the concentration of cortisol 
levels in the blood, the overall success of the corticosteroid suppression can be determined for the 
different routes of injection of dexamethasone. The initial hypothesis is that blood cortisol 
concentrations in horses will be equally suppressed in horses given dexamethasone intravenously as 
in horses given dexamethasone 1M. Thus, either method of administration will lead to equal 
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suppression of the pituitary-adrenal axis in nonnal horses. As Pars Intermedia Pituitary adenoma with 
absent or mild clinical signs is currently diagnosed using a dexamethasone suppression test or a 
combined dexamethasone suppression/thyroid releasing hormone test, this study will attempt to prove 
that the two methods of injection are generally equivalent in their suppression of cortisol levels. 
2. Materials and Methods 
Six mixed breed horses between 4 and 17 years old and weighing between 398 and 629 kg (878 
and 1,387 lb) were used. The horses were used in a random cross-over study where they were 
randomly assigned to treatment groups by drawing IV or 1M from a hat Blood samples will then be 
collected before dexamethasone injection and at three hour intervals following injection, concluding 
with a sample at t==24 hours .. A two week washout period will follow, after which the horses will 
be treated with the opposite route of dexamethasone administration, once again followed by 
collection of samples. 
Jugular vein catheters were inserted at 8 AM, and the initial blood samples were drawn at 8:30 
AM, whereby they were immediately placed into an evacuated purple top tube containing EDT A. 
Dexamethasone (40 micrograms/kg of body weight) was then administered. The remaining blood 
samples were drawn at the specified times, and also placed into a tube containing EDT A. 
Following collection, the blood samples were centrifuged, and the plasma was collected and stored 
at -70 C until analyzed. Following thawing, cortisol concentration was then determined by use of the 
Count-A-Coat radio-immunoassay procedure produced by Diagnostic Products Corporation. In this 
procedure, 1-125 labeled cortisol competes for a fixed time with cortisol in the equine plasma sample 
for antibody sites. Because the antibody is immobilized to the wall of a polypropylene tube, simply 
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decanting the supernatant suffices to terminate the competition and to isolate the antibody-bound 
fraction of the radiolabeled cortisol. Counting the tube in a gamma counter then yields a nurrlber, 
which converts by way of a calibration curve to a measure of the cortisol present in the patient 
sample. 
Means and SEM for cortisol concentrations were estimated using proc MEANS in SAS. Analysis 
of variance was performed on data using the mixed procedure (pROC MIXED) in SAS to compare 
time and treatment interactions. Significant differences were determined a P<O.05. 
3. Results 
The results showed that there was no difference in 1M versus IV treatment (P=.1878). There was 
a significant decrease in cortisol over time (P<O.05). However, there was no time and treatment 
interaction (P=. 9797). 
4. Discussion 
As was expected, cortisol concentrations were seen to decrease over time (Figure 1). The results 
of this study showed that there was no significant difference in the overall suppression of cortisol 
when dexamethasone was injected IV and 1M. Thus, both IV and 1M injection of dexamethasone 
equally suppressed the pituitary-adrenal axis. In the future, this information will be useful to 
practitioners in determining which route of administration is the best for testing for Pars Intermedia 
Pituitary adenoma. Pituitary tumors are common in older horses and require blood testing for 
diagnosis. The current methods of diagnosing this disease require the administration of 
dexamethasone (either 1M or IV) followed by IV administration of Thyroid Releasing Hormone. The 
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blood cortisol concentration is then measured at prescribed time intervals after dexamethasone 
injection. Previously, there was no information on whether the route of dexamethasone 
administration effected the interpretation of the test or whether there was a difference in cortisol 
blood concentrations depending on the route of dexamethasone administration. However, the results 
of this study have demonstrated that, in normal horses, the route of administration of dexamethasone 
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Figure 1: Treatment with dexamethasone IM. 
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Figure 2. Treatment with dexamethasone IV 
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Figure 3. Combined results for dexamethasone IV and 1M 
The cover page, part I, General Information and all applicable sections of part II, Detailed Information must be completed 
for all research and teaching activities. 
Submit 3 typed copies to: 
Office of laboratory Animal Care (OlAC) 
A205 Veterinary Teaching Hospital 
Phone # 974-5634 
HORSE ENDOCRINOLOGY 
Title of Project/Course 
Frank M. Andrews, DVM 
Principal Investigator/Instructor 
423-974-5704 UTCVM 
Wk, Phone College 
Lg. Animal Clinical Sciences 
Department 
«( our signature as P,I., Co-investigator, or Department Head on this application verifies that: (1) the information herein is true 
and correct and that you are familiar with and will comply with the legal standards of animal care and use established under 
fed~:=!£nd state laws and policies as well as university policies; (2) the proposal has received approval for scientific and/or 









To be completed for all Research and Teaching Activities. 
General Information 
1. This is a [X] New [ ] 3-year rewrite proposal for 
[ ] Research [ ] Teaching 
2. Anticipated: start date March 9, 1998 end date May 1, 1998 
3. [] Yes [X] No This protocol includes the use of farm animals used or intended for use as food or 
fiber, or livestock or poultry used or for improving animal nutrition, breeding, management, or production 
efficiency, or for improving the quality of food or fiber. 
4. Veterinarian responsible for clinical care 
[ ] OLAC Staff Veterinarians 
[X] Dr. Dallas Goble 
[ ] LACS Ambulatory Service for the Department of Animal Science 
[ ] Other, list If other, clinical veterinarian must follow the IACUC "Attending 
Veterinarian/Researcher Veterinarian" policy. 
5. Funding Source: Large Animal Clinical Sciences 
B. Animal Housing Facilities 
II 
In order to provide assurance of humane care and use of laboratory animals, all animal housing facilities on the UTK 
campus will be operated according to federal laws, AftALAC and NIH Guidelines, and the Guide for the Care and Use of 
Agricultural Animals in Agricultural Research and Teaching as appropriate. Housing of animals, including those actively on 
experiment, for periods longer than 12 hours, is restricted to facilities meeting such guidelines and laws. 
Please check your preferred housing location. 
[] College of Arts and Sciences Facility in the Walters Life Sciences Building (WLS). 
[] College of Human Ecology Animal Facility in the Jessie Harris Building. 
[] College of Veterinary Medicine (CVM) Laboratory Animal Facility VTH/Cherokee 
[ X ] CVM Large Animal Clinical Sciences in VTH/Cherokee Farm 
[] UT Medical Center Lab Animal Facility 
[] Brehm Animal Science Building Room ___ _ 
[] IACUC Approved Satellite Facility List bldg/room # ___________ _ 
[] *Other 
* Any newly established facility must be approved before housing animals. 
In accordance with NIH Guidelines and Federal Law, the IACUC formally reviews all animal housing facilities and satellites 
semi-annually and files a report to the Office for Protection from Research Risks (OPRR) in Washington, DC and the 
I 'f'lited States Department of Agriculture (USDA). 
\. " 
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Common Name Stra i nIB reed Sex Weight/Age Source #/project Maximum per day 
Equine F 6-30 yrs UTCVM 6 6 
2. Animals will be removed from the animal housing facility: 
3. 
[X] No 
[ ] Yes. Please answer the following: 
1. Animals will be taken to (bldg/room number): ________ _ 
2. Animal manipulations that will be performed in the laboratory include: _____ _ 
3. Estimated total time period live animals will be kept in the laboratory: hours 
4. Animals will be returned to the facility YES NO 
Disposal of animals after completion of activity: 
[X] Return to production/breeding unit/facility inventory 
[ ] Slaughter, (must conform to the Humane Slaughter of Livestock, 9 CFR, part 313) 
[ ] Sold 
[ ] Transfer to another research project (if yes, project title and investigator) 
[ ] Euthanized 
[ ] Returned to owner 
[ ] Other (Please describe) ______________________ _ 
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Non-Technical Summary 
A complete non-technical summary is required for conformance with PHS Policy. Non-technical summary must be 
submitted as an attachment and should not exceed mo (2) pages. Non-technical summary must be written to 
ensure comprehension by non-scientists on an 8th grade level. 
It must contain the following: 
E. 
1) objectives of the research or teaching activity; 
2) species and number of animals; 
3) methods used to reduce any experimental stress or discomfort 
4) schedule of the course or the study procedures performed on animals during each phase 
5) benefits, outcome and results expected in non-technical terms. 
Pituitary tumors are common in older horses and require blood testing for diagnosis. Current 
methods of diagnosing this disease in horses requires the administration of dexamethasone either 
intravenously (in the vein (IV)) or intramuscular (in the muscle (1M)) and Thyroid Releasing Hormone 
IV and measurement of blood cortisol (steroid) concentration at prescribed time intervals after 
injection. Unfortunately, there is no information on whether the route of dexamethasone 
administration (IV vs. 1M) effects the interpretation of the test or whether there is a difference in 
cortisol blood concentrations depending on the route of dexamethasone administration. The 
objective of this study is to detennine if there is a difference in blood cortisol concentration in horses 
given dexamethasone IV versus dexamethasone 1M. The data from this experiment will help 
determine if the route of administration affects the results of the test in normal horses so that this test 
can be used as a diagnostic test in horses suspected of having pituitary adenoma. 
We propose to use 6 healthy 7·30 year old horses. This is the age range in which the disease 
occurs in horses. 
The horses will be placed in box stall during the 24 hour blood collection phase with feed and 
water to minimize stress. At approximately 8:00 am in the morning the horses will be placed in an 
equine stocks with a rope tied in front and behind. The horses will be lightly restrained !'lith a lead 
shank and halter and area over the jugular vein clipped and prepared with provodone iodine sterile 
scrub. Lidocaine (approximatery 3 cc) will be injected subcutaneously over the jugular vein to locally 
anesthetize the skin to the minimize pain of catheter placement. The intravenous catheter will be 
placed in the vein and sutured in place to prevent the horse from removal during the study period. 
The horse will then be place in the stall and blood sampling started at approximately 8:30 pm (T=O). 
After the first blood sample is drawn then the horse will be injected with a low dose of dexamethasone 
(40lJg/kg, IV or 1M). A blood samples will be taken 3 hour after injection, then TRH (1.0 mg, IV) will be 
administered. Blood samples will then be taken at 3.5, 6, 9, 12, 18, and 24 hours after administration 
of dexamethasone. Each horse will receive the dexamethasone IV followed by a two week rest, then 
receive the dexamethasone 1M in the same manner. Some horses will receive the injections in reverse 
order to remove any bias due to effect of treatment. The blood samples will be analyzed later for 
cortisol concentrations. 
We expect to determine if the route of dexamethasone administration effects the cortisol 
concentrations measured. This information will help practitioners in determining which route of 
administration is the best for using this diagnostiC test to determine horses that have pituitary 
adenoma. 
Flow Sheet or Table of Groupings 
Pertinent information (Le., numbers of animals, experimental manipulations) should be provided on a flow 
sheet. The Committee members should be able to follow every manipulation of the animal from 
experiment initiation to completion (e.g., day one, group one, treatment; day two. etc.). Please provide as 
a separate page. 
See attached Page 
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Flow Sh~etor Table of Groupings 
Pertinent information (Le., numbers of animals. experimental manipulations) should be provided on a flow 
sheet. The Committee members should be able to follow every manipulation of the animal from 
experiment initiation to completion {e.g., day one, group one, treatment; day two. etc.}. Please provide as 
a separate page. 
Flow Sheet 
8:00 am-horses placed in equine stocks and IV jugular catheter placed. 
8:30 am-blood sample taken, Dexamethasone (40 pg/kg, IV) administered. 
11 :30 am-blood sample taken, TRH (1.0 mg, IV) administered. 
12:00 pm-blood sample taken 
2:30 pm-blood sample taken 
5:30 pm-blood sample taken 
8:30 pm-blood sample taken 
11 :30 am-blood sample taken 
2:30 am-blood sample taken 
5:30 am-blood sample taken 
8:30 am-blood sample taken 
IV catheter removed and horse returned to stall or pasture at Cherokee 
Same protocol repeated 2 weeks later with 1M injection of Dexamethasone. 
\ 
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F. Qualifications of Personnel 
list all individuals who will be working with the animals on this project. Include all investigators, student 
employees, post-doctoral researchers, staff research associates and laboratory assistants who will 
actually work with the animals. If personnel do not have experience, state how they wifl be trained. 
The Occupational Health Program (OHP) is available for all personnel who work with laboratory 
animals. Any personnel in a high risk category (e.g. handling primates, wild animals or any animals at risk 
of infection with rabies) must participate. 
N an1elDegree( s) OHP* Procedure(s)/Description of Relevant Experience 
Dr. Frank M. Andrews IV catheter placement, injection of pharmaceutical agents, collection of 
bloodlDr. Andrews has experience as veterinarian and previous 
experience with pharmaceutical agents used per UT-ACUC# 665. 
Janell Kapp (Student) Will assist Dr. Andrews in above procedures. She has been trained by 
Dr. Andrews in the above procedures. 
.. 
*If an individual having animal contact IS not currently enrolled In the occupational health program call the 
OLAC (974-5634) for information on enrolling. 
G. Animal Welfare 
1. This project involves pain or distress [ ] yes [X] no 
The USDA (Policy #12) requires that the principal Investigator must provide a written 
narrative of the sources consulted to-determine whether alternatives"or refinements exist· 
to procedures which may reduce pain or distress. 
If yes. the minimal written narrative should include: 
a. the databases searched or other sources consulted, 
b. the date of the search and the years covered by the search, 
c. key words and/or search strategy used, 
d. a narrative written in such a way that the IACUC can readily assess whether the 
search topics were appropriate and whether the search was sufficiently thorough 
2. Does the proposed research duplicate any previous work? [ ] yes [X] no If yes, explain why it 
is scientifically necessary to replicate the experiment. 
3. Why have you selected the particular species proposed in this project? 
To improve a diagnostic procedure for pituitary tumors in horses. 
4. Provide an explanation of how the numbers of animals to be used were derived. If used in an 
experiment (test a hypothesis) numbers should be based on scientific and statistical requirements 
(power tests) to achieve objectives. 
In previous experiments we have determined variability in plasma cortisol. Six 




Check and complete those sections A - E that are relevant to your project. 
REMOVE ALL SECTIONS NOT APPLICABLE TO YOUR PROPOSAL. 
A. Non-Surgical Procedures (Pertains to any experimental procedure-
including non-surgicat pre-surgical and post-surgical procedures using animals) 
[ ] NO [ X] YES: COMPLETE SECTION A 
B. Surgical Procedures (Pertains to any surgical procedure, including non-survival surgery. If other 
procedures are done on animals prior to or after surgery, comprete section A and other applicable 
sections.) 
[X]NO [ ] YES: COMPLETE SECTION 8 
C. Field Studies Involving Wild Animals (Request this section from the OLAC office) 
[X] NO [ ] YES: COMPLETE SECTION C 
D. Hazardous Agents/Prescription Drugs/Controlled Substances 
[X] NO [ ] YES: COMPLETE SECTION 0 
E. Euthanasia 
[Xl NO [ ] YES: COMPLETE SECTION E 
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Section A . 
Non-Surgical Procedures 
Site of housing prior to study:-.::C=;.V..:.....oo..:M~C=h=e=r-"'o=k=e=e~F-""a=r=m.::...-__________ _ 
Bldg. 




2. Health Assessment: 
(r 
How often and by whom will the clinical condition of animals be monitored? 
Once before the experiment is conducted and daily during the investigation. 
What are the anticipated health changes? 
None 
What methods will be used to monitor health changes? 
Temperature, Pulse, and Respiratory Rate, general physical examinations and observation 
What criteria will be used for removing animals from the study prematurely? 
Any animal exhibiting any abnormal clinical sign, including increased heart rate, respiratory rate, or 
temperature. 
3. Study Procedures: Please check the following items that apply and fill out appropriate parts of this section. 
[ ] Polyclonal Antibody production* 
[ X] Blood* or other body fluid withdrawal, tissue collection, injections 
[ ] Restraint with mechanical devices 
[ ] Projects involving nutritional deficiencies, tumor and disease models or toxicity testing 
[ ] Anesthesia or analgesia* (for non-surgical procedures) 
[ ] Behavioral Studies 
* The IACUC has approved guidelines for these procedures. Deviations must be justified. 
Polyclonal Antibody production 
Describe procedure. antigen and adjuvants used, the ratio of antigen to adjuvant and routes and volumes of injection: (Vol. 
should be < 0.25 ml per injection site; subcutaneous route is recommended) 
Blood or body fluid withdrawal/tissue collectionl injections 
Describe in detail method(s). needle sizes, volume(s) collected or administered. and frequency of collection or injections: 
Blood will be collected from the preplaced 16 ga 5 ~ inch IV catheters using a syringe. 10ml samples will 
be collected at O-time, 3, 3.5, 6, 9, 12, 15, 18, and 24 hours after injections of dexamethasone. 
Approxinlately, 190 ml of blood will be taken from each horse, ,vhich comprises less than 0.5% of the 
total blood volume of a 450 kg (1000 Ib) horse. By preplacing the catheter we will avoid having to stick 
(e horse ,vith needles 9 times during the 24 hour period. 
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Part II 
Section A .. Non-Surgical Procedures 
continued 
Describe device, duration of restraint, frequency of observation, conditioning procedures and steps to assure comfort and 
well-being: 
The horses wiIJ be lightly restrained in an equine stocks for intravenous catheter placement and housed in a box 
stall and restrained with a lead shank and halter for blood collections. 
Behavioral Studies 
Describe in detail types of behavioral manipulations, including placement in testing chambers or apparatus, use of aversive 
stimuli, duration of test periods, and frequency of test periods. 
N/A 
Nutritional deficiencies/Ascites tumor, monoclonal 
antibody production/Disease. neoplasia modelslToxicity testing 
Describe methodology. State objective criteria used to assess physical condition and pain and distress during course of 
study_ Include clinical signs or manifestations expected from the procedure. What criteria will be used to determine a 
humane endpoint before severe morbidity and death? 
N/A 
( 
Anesthesia/AnalgesialTranquilization (Other than Surgery Section B) 
Adequate records describing anesthetic monitoring and recovery must be maintained and available to the 
attending veterinarian and animal care staff. 
Drug Dose Route Frequency For which procedure 
Name and qualifications of person administering drugs: ____________________ _ 
Describe: frequency and methods to be used to monitor level of anesthesia (e.g., blood pressure, heart rate, pedal reflex, 
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RESUl-TS OF OE)( SUPPRESSION TEST 








































BEE 1M - 3/13/98 IV - 4/1/96 
t=O 46.154 75.915 
t;;1a 12.528 22.845 
C~ t=1b 12.653 22.325 
t=1 average 12.5905 22.585 
t=2a 11.114 19.112 
t;;:2b 12.557 19.641 
t=2 average 11.8355 19.3765 
t=3 6.9263 11.001 
t=4 7,3145 7.24Q8 
t-5 7.3133 5.5151 
t=6 6.8168 4.3959 
t=7 4.5605 5.1187 
t=8 8.4522 4.8861 
t;.::9a 10.408 5.883 
t=9b 7.0322 7.4805 
t=9 average 6,7201 6.66175 
t=10a 10.669 10,64 
t;;10b 9.557 12.442 
t= 10 average 10.113 11.641 
( 
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97015 IV - 3/13/96 1M - 4/8196 
t=O 79.454 77.461 
C . t=1a 29.553 53.144 
,J t=1b 25.988 43.266 
t=1 average 27,7705 48.205 
t;:28 20.401 38.01 
t=2b 17.288 40.286 
t=2 average 18,8445 39.148 
t=3 9.3124 13,228 
t-4 8.8875 7.2369 
t=5 8.9025 6.3026 
t=6 14.227 7.765 
t=7 5.7711 
t=8 5.2055 4.5962 
t=9a 10.825 5.7912 
t=9b 10.901 5.0388 
t=9 average 10.863 5.415 
t .. 108 11.765 12.312 
t=10b 8.4247 12.858 




97008 IV - 3/13/98 1M - 4/6198 
t=O 114.26 127,02 
C t;1a 37.08 28.67 
p t=1b 34.077 26.536 
t=1 average 35,5785 27,603 
t=2a 32,16 21.636 
t-2b 27.959 20.476 
t=2 average 30.0595 21.056 
t=3 16.377 11.424 
t=4 10.152 8.7517 
t;:5 7.0485 9.3114 
t=6 5.3818 7.319 
t=7 9.3906 
t=8 5.3365 6.0063 
t-9a 7.0399 6.9891 
t=9b 6.4836 5.1593 
t=9 average 6.76175 6.0742 
t=10a 10.746 7.9763 
t;;10b 8.4669 8.4617 
t= 1 0 average 9.60645 8.219 
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97009 1M - 3/13198 IV - 4115/98 
t;;:O 129.24 64.426 
t=1a 47.606 18.219 
( . .- t=1b 38.678 23.173 
t=1 average 43.142 20.696 
t-;2a 32.973 20.641 
t=2b 29.192 17.293 
t=2 average 31.0825 18.967 
t=3 19.759 8.6819 
t-4 16.39 10.369 
t=5 9.973 12.011 
t=6 7.4113 5.641 
t=7 5,9264 
t=8 8.5624 5.0389 
t=9a 10.64 16.854 
t=9b 7.9084 13.458 
t=9 average 9.2742 15.156 
t;;;10a 49.438 51.02 
t=10b 52.093 55.188 




97018 IV - 3/13/98 1M - 4/15/98 
t;;:O 163.19 95.919 
t=1a 56.487 37.39 C t=1b 51.607 34.373 
t=1 average 54.047 35.8815 
t-2a 45.155 28.714 
t=2b 41.21 25.88 
t=2 average 43.1825 27.297 
t=3 20.556 12,586 
t-4 9.5262 9.7436 
t=5 10.155 6.3317 
t=6 6.3578 8.3979 
t=7 4,1931 
t;;.;8 55.39 5.2392 
t=9a 54.402 4.3358 
t=9b 41.587 3.7229 
t=9 average 47.9945 4.02935 
t;;;10a 99.443 27.97 
t=10b 92.192 28.417 
t= 10 average 95.8175 28.1935 
( 
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